Canlyniadau Chwilio - Teerha Piratvisuth

Mireinio'r Canlyniadau
  1. 1
    Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B

    Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B gan Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B gan Teerha Piratvisuth, George Lau, You‐Chen Chao, Rui Jin, Anuchit Chutaputti, Q.-B. Zhang, Tawesak Tanwandee, Peter Button, M. Popescu

    Cyhoeddwyd 2008
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

    Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update gan Yun–Fan Liaw, Nancy Leung, Jia‐Horng Kao, Teerha Piratvisuth, Edward Gane, Kwang‐Hyub Han, Richard Guan, George Lau, Stephen Locarnini

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study gan Teerha Piratvisuth, Tawesak Tanwandee, Satawat Thongsawat, Wattana Sukeepaisarnjaroen, Juan Ignacio Esteban, Marta Bes, Bruno Köhler, Ying He, Magdalena Lange, David Morgenstern, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2021
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

    HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B gan Michael Fried, Teerha Piratvisuth, George Lau, Patrick Marcellin, Wan-Cheng Chow, Graham Cooksley, Kang-Xian Luo, Seung Woon Paik, Yun–Fan Liaw, Peter Button, M. Popescu

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

    Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a gan Patrick Marcellin, Ferruccio Bonino, George Lau, Patrizia Farci, Cihan Yurdaydın, Teerha Piratvisuth, Rui Jin, Selım Gürel, Zhi‐Meng Lu, Jian Wu, M. Popescu, Stephanos J. Hadziyannis

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care

    A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care gan Christopher McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando Lopes Gonçales, Ioannis Goulis, Fred Poordad, Nezam H. Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin, Michael Fried

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

    Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels gan Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Jidong Jia, Stefan Zeuzem, Edward Gane, Yun–Fan Liaw, Qing Xie, Jenny Heathcote, Henry Lik‐Yuen Chan, Harry L.A. Janssen

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a

    Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a gan Patrick Marcellin, George Lau, Stefan Zeuzem, E. Jenny Heathcote, Paul J. Pockros, K. Rajender Reddy, Teerha Piratvisuth, Patrizia Farci, Wan‐Cheng Chow, Jidong Jia, Woon Ki Paik, Neil Wintfeld, N. Pluck

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †

    Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # † gan Maurizia Rossana Brunetto, F. Moriconi, Ferruccio Bonino, George Lau, Patrizia Farci, Cihan Yurdaydın, Teerha Piratvisuth, Kangxian Luo, Yuming Wang, Stephanos J. Hadziyannis, Eva Wolf, Philip McCloud, Richard Batrla, Patrick Marcellin

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

    Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B gan Ferruccio Bonino, Patrick Marcellin, George Lau, S. Hadziyannis, Rui Jin, Teerha Piratvisuth, Georgios Germanidis, Cihan Yurdaydın, M. Diago, Selım Gürel, Lai My, Maurizia Rossana Brunetto, Patrizia Farci, M. Popescu, Philip McCloud

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B gan Teerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Henry Lik‐Yuen Chan, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Hugo Cheinquer, Rashidkhan Pathan, Yuhong Dong, Aldo Trylesinski

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

    Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B gan Patrick Marcellin, George Lau, Ferruccio Bonino, Patrizia Farci, Stephanos J. Hadziyannis, Rui Jin, Zhi‐Meng Lu, Teerha Piratvisuth, Georgios Germanidis, Cihan Yurdaydın, M. Diago, Selım Gürel, Ming‐Yang Lai, Peter Button, N. Pluck

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy

    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy gan Teerha Piratvisuth, Piyawat Komolmit, Henry C. B. Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael P. Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region

    Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region gan Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, Mindie H. Nguyen, Suthat Liangpunsakul, Teerha Piratvisuth, Apichat Kaewdech

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B gan George Lau, Teerha Piratvisuth, Kang Luo, Patrick Marcellin, Satawat Thongsawat, Graham Cooksley, Edward Gane, Michael Fried, Wan Cheng Chow, Seung Woon Paik, Wen Yu Chang, Thomas Berg, Robert Flisiak, Philip McCloud, N. Pluck

    Cyhoeddwyd 2005
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

    Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report gan Henry Lik‐Yuen Chan, A. Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L. Tillmann, Jia‐Horng Kao, Jidong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry L.A. Janssen, Patrick Marcellin

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies gan Teerha Piratvisuth, Jinlin Hou, Tawesak Tanwandee, Thomas Berg, Arndt Vogel, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Kairat Madin, Konstantin Kroeniger, Ashish Sharma, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C gan Yun–Fan Liaw, Jidong Jia, Henry Lik‐Yuen Chan, Kyunghwa Han, Tawesak Tanwandee, Wan‐Long Chuang, Dianhui Tan, X. Y. Chen, Edward Gane, Teerha Piratvisuth, L. Chen, Qing Xie, Joseph J.�Y. Sung, Cynthia Wat, Coen Bernaards, Y. Cui, Patrick Marcellin

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement

    Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement gan Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, A. Thompson, Jidong Jia, Jinlin Hou, Cosmas Rinaldi Adithya Lesmana, Adityo Susilo, Yasuhito Tanaka, Wah‐Kheong Chan, Ed Gane, Arlinking Ong-Go, Seng Gee Lim, Sang Hoon Ahn, Ming‐Lung Yu, Teerha Piratvisuth, Henry Lik‐Yuen Chan

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: